Serum M3/M21 in ovarian cancer patients

British Journal of Cancer

Volumn 76, Issue 10, 1997, Pages 1387-1389

  Tempfer, C ^a   Hefler, L ^a   Haeusler, G ^a   Sliutz, G ^a   Hanzal, E ^a   Reinthaller, A ^a   Kainz, C H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

M3 M21; Ovarian cancer; Tumour marker

Indexed keywords

CYTOKERATIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 0030712876     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.565     Document Type: Article

References (8)

1. Bormer O (1994) From tissue polypeptide antigen to specific cytokeratin assays. Tumor Biol 15: 185-187
2. Devine P (1994) All cytokeratin assays are not the same. Ear J Clin Chem Clin Biochem 32: 939-940
3. Gion M, Mione R and Becciolini A (1994) Relationship between cytosol TPS, TPA and cell proliferation, Int J Biol Markers 9: 109-114
4. Moll R, Franke WW and Schiller DL (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia. tumours and cultured cells. Cell 31: 11-24
5. Sabbatini S, Monti M and Fini A (1988) Tissue polypeptide antigen (TPA) modifications in hepatic cirrhosis, aggressive chronic hepatitis, persistent chronic hepatitis, and in minimal pathology. Int J Biol Markers 3: 127-128
6. Sundstrom BE and Stigbrand T (1994) Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 9: 102-108
7. Tempfer C, Hanzal E and Zeillinger R (1996) The new serum tumor marker M3/M21 in the follow-up of breast cancer patients. Anticancer Res 16: 2135-2138
8. Thigpen J, Vance R and Khansur T (1993) Second line chemotherapy for recurrent carcinoma of the ovary. Cancer 71: 1559-1564